About the company
Viatris, the result of the merger between Upjohn and Mylan, has quickly established itself as a major player in the global pharmaceutical industry. With a presence in over 165 countries, the company has solidified its position as one of the largest generic drug manufacturers in the world. In fact, generics and biosimilars alone account for approximately 40% of Viatris' total sales, showcasing the company's expertise in producing affordable alternatives to brand-name medications. However, Viatris is not solely reliant on generics and biosimilars for its success. The remaining 60% of the company's sales are derived from a portfolio of legacy products, which includes well-known medicines such as Lipitor, Norvasc, Lyrica, and Viagra. These established brands continue to be in demand and contribute significantly to Viatris' revenue stream. To ensure future growth and innovation, Viatris has identified three key therapeutic areas to focus on: dermatology, ophthalmology, and gastroenterology. These areas have been strategically chosen due to their potential for expansion and the company's existing expertise in these fields. By concentrating their efforts on these specific areas, Viatris aims to develop new and improved treatments that address unmet patient needs and improve overall healthcare outcomes. In dermatology, Viatris aims to develop innovative solutions for various skin conditions, including acne, psoriasis, eczema, and fungal infections. By leveraging their expertise in the formulation and manufacturing of topical medications, Viatris endeavors to create effective and accessible treatments that improve the quality of life for patients dealing with these conditions. In ophthalmology, Viatris focuses on advancing treatments for eye disorders such as glaucoma, dry eye syndrome, and age-related macular degeneration. With an aging population and increasing cases of these eye conditions, the demand for innovative therapies is on the rise. Viatris aims to provide patients with improved medications and delivery systems to address these needs and improve visual health outcomes. Gastroenterology is another key area where Viatris aims to make significant contributions. With the prevalence of digestive disorders such as irritable bowel syndrome, inflammatory bowel disease, and acid reflux, there is a growing need for innovative treatments that alleviate symptoms and improve patients' quality of life. Viatris is committed to developing novel therapies and expanding its product portfolio in this therapeutic area. In addition to these three key areas, Viatris covers a wide range of therapeutic categories, including cardiovascular, central nervous system, infectious diseases, oncology, respiratory, and women's health. The company's diverse product portfolio allows it to cater to the healthcare needs of patients across various medical conditions. With its global reach, expertise in generics, and focus on innovation, Viatris is poised to play a crucial role in shaping the pharmaceutical industry. By providing affordable medications to a wide range of patients worldwide and driving advancements in key therapeutic areas, the company remains committed to improving global healthcare outcomes and making a positive impact on patients' lives.
Website: https://www.viatris.com
Data updated: June 2, 2026
